Entry inhibitors offer an alternative strategy to treat AIDS.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Related links
Related links
Related links in Nature Research
https://doi.org/10.1038/NatureBiotechnology21,470-471(01May2003)
US bioterrorism countermeasures research builds across a broad front
Web links
Rights and permissions
About this article
Cite this article
Katsnelson, A. Biotech jostles with pharma for slice of HIV market. Nat Biotechnol 24, 3–4 (2006). https://doi.org/10.1038/nbt0106-3
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0106-3
This article is cited by
-
Monoclonals expand into neural disorders
Nature Biotechnology (2006)